Adaptive Biotechnologies Corporation
NASDAQ:ADPTBiotechnology
+$0.61 today
- Market cap
- $4.61B
- Beta
- 2.15
- P/E (TTM)
- -54.5
- EPS (TTM)
- -$0.32
Volume 2.21M
Average 1.94M
ADPT Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Adaptive Biotechnologies CorporationNASDAQ: ADPT
Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026
Capital expenditures growth accelerates
Q2 FY2026 capital expenditures of $1.18M (cash outflow) rose 80.8% year over year, ahead of the +29.4% change in trailing-twelve-month capital expenditures. Sequentially, it rose 48.7% from the prior quarter. Over 3 fiscal years it compounded at -43.4% a year.
Context
- Capital expenditures amounted to 1.1% of revenue in FY2025, down 1.0 pp from a year earlier.
- Capital expenditures grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +80.8% holds above the trailing-twelve-month pace of +29.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (2.96M) USD
- Year-over-year change
- +19.2%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (2.96M) | +19.2% |
| FY2024 | 2024-12-31 | (3.66M) | +65.7% |
| FY2023 | 2023-12-31 | (10.7M) | +34.6% |
| FY2022 | 2022-12-31 | (16.35M) | +73.5% |
| FY2021 | 2021-12-31 | (61.75M) | — |
Capital Expenditures vs competitors
How ADPT compares with its peers on the latest reported figures
- ADPT's LTM Jun 2026 capital expenditures of $3.03M is the 5th largest of the 10 companies compared; the peer median is $2.01M.
- Its year-over-year change of +29.4% is the 3rd highest of 10, against a peer median of -48.1%.
- Capital expenditures amounts to 1.0% of revenue for ADPT, versus a peer median of 5.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $73.11M | +292.9% | +44.8% | 5.4% | |
| LTM Jun 2026 | $29.13M | -44.0% | -18.7% | 6.5% | |
| LTM Sep 2026 | $17.46M | +103.6% | +169.1% | 2.6% | |
| LTM Jun 2026 | $13.39M | +24.6% | -32.7% | 8.6% | |
| LTM Jun 2026 | $3.03M | +29.4% | -43.4% | 1.0% | |
| LTM Mar 2026 | $2.01M | -48.1% | -11.7% | 0.9% | |
| LTM Sep 2026 | $202K | -65.9% | -17.3% | 35.4% | |
| LTM Mar 2026 | $85K | -76.2% | +26.0% | 0.0% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $20K | -98.5% | +83.5% | — |
| LTM Jun 2026 | $15K | -59.5% | — | — | |
| Peer median (excluding ADPT) | $2.01M | -48.1% | +7.1% | 5.4% | |
Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (207.28M) | (200.19M) | (225.25M) | (159.6M) | (59.5M) |
| Depreciation & Amortization | 13.95M | 20.92M | 22.23M | 19.26M | 17.83M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 53.61M | 51.48M |
| Change in Working Capital | (56.82M) | (71.55M) | (46.18M) | (17.45M) | (57.77M) |
| Accounts Receivables | (7.36M) | (22.65M) | 2.03M | (3.74M) | (8.65M) |
| Inventory | (5.2M) | 817K | (2.84M) | 1.94M | (998K) |
| Accounts Payables | 3.94M | 7.11M | (5.41M) | 671K | 665K |
| Other Working Capital | (48.19M) | (56.83M) | (39.97M) | (16.32M) | (48.79M) |
| Other Non-Cash Items | 57.42M | 66.87M | 92.88M | 8.97M | 1.96M |
| Operating Cash Flow | (192.73M) | (183.95M) | (156.32M) | (95.21M) | (45.99M) |
| Capital Expenditures | (61.75M) | (16.35M) | (10.7M) | (3.66M) | (2.96M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (316.54M) | (278.78M) | (429.56M) | (244.26M) | (181.71M) |
| Sales of Investments | 559.5M | 298.03M | 569.9M | 325.71M | 222.62M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 181.21M | 2.91M | 129.65M | 77.79M | 37.95M |
| Debt Repayment | 0 | 124.38M | 0 | 0 | 0 |
| Common Stock Issued | 26.72M | 7.89M | 2.25M | 241K | 30.4M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 429K | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 27.15M | 132.26M | 2.25M | 241K | 30.4M |
| Effect of Forex Changes | 0 | (260K) | (534K) | 0 | 0 |
| Net Change in Cash | 15.63M | (49.04M) | (24.97M) | (17.18M) | 22.37M |
| Free Cash Flow | (254.47M) | (200.29M) | (167.02M) | (98.88M) | (48.95M) |
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
Intrinsic Alpha fair value
Locked
Current Price
$28.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.